DK2376121T3 - Slidgigtbehandling - Google Patents
Slidgigtbehandling Download PDFInfo
- Publication number
- DK2376121T3 DK2376121T3 DK09833924.5T DK09833924T DK2376121T3 DK 2376121 T3 DK2376121 T3 DK 2376121T3 DK 09833924 T DK09833924 T DK 09833924T DK 2376121 T3 DK2376121 T3 DK 2376121T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- csf
- antibody
- leu
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Virology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Polarising Elements (AREA)
- Glass Compositions (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Claims (7)
1. Antagonist af GM-CSF til anvendelse i behandling af slidgigt, hvor antagonisten er et antistof specifikt til GM-CSF.
2. Sammensætning omfattende en GM-CSF-antagonist, til anvendelse i behandling af slidgigt, hvor antagonisten er et antistof specifikt til GM-CSF og yderligere, hvor sammensætningen yderligere omfatter én eller flere farmaceutisk acceptable bærestoffer og/eller fortyndingsmidler.
3. Antistof til anvendelse ifølge krav 1 eller krav 2, hvor antistoffet er en kimærisk, humaniseret eller humant antistof.
4. Antistof til anvendelse ifølge krav 3, hvor antistoffet er et humaniseret antistof.
5. Antistof til anvendelse ifølge et hvilket som helst af krav 1- 4, hvor antistoffet omfatter en tung-kæde variabel region, som er mindst 90% homolog til aminosyresekvensen ifølge SEQ ID NO: 3, og en let-kæde variabel region, som er mindst 90% homolog til aminosyresekvensen ifølge SEQ ID NO: 4.
6. Antistof til anvendelse ifølge krav 5, hvor antistoffet omfatter en tung-kæde variabel region, som er mindst 95% homolog til aminosyresekvensen ifølge SEQ ID NO: 3, og en let-kæde variabel region, som er mindst 95% homolog til aminosyresekvensen ifølge SEQ ID NO: 4.
7. Antistof til anvendelse ifølge krav 5, hvor antistoffet omfatter aminosyresekvensen af den tung-kæde variable region ifølge SEQ ID NO: 3, og aminosyresekvensen af den letkæde variable region ifølge SEQ ID NO: 4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13967908P | 2008-12-22 | 2008-12-22 | |
| US16448609P | 2009-03-30 | 2009-03-30 | |
| PCT/AU2009/001672 WO2010071924A1 (en) | 2008-12-22 | 2009-12-21 | Osteoarthritis treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2376121T3 true DK2376121T3 (da) | 2016-05-30 |
| DK2376121T4 DK2376121T4 (da) | 2021-08-16 |
Family
ID=42286786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09833924.5T DK2376121T4 (da) | 2008-12-22 | 2009-12-21 | Slidgigtbehandling |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9243061B2 (da) |
| EP (2) | EP3056217B1 (da) |
| JP (3) | JP5727379B2 (da) |
| KR (2) | KR101898982B1 (da) |
| CN (2) | CN102271705A (da) |
| AU (1) | AU2009329814B2 (da) |
| BR (1) | BRPI0918356B1 (da) |
| CA (1) | CA2746827C (da) |
| CY (1) | CY1117698T1 (da) |
| DK (1) | DK2376121T4 (da) |
| ES (2) | ES2886063T3 (da) |
| HK (1) | HK1226938A1 (da) |
| HR (1) | HRP20160577T4 (da) |
| HU (1) | HUE028615T2 (da) |
| PL (1) | PL2376121T5 (da) |
| RU (2) | RU2712273C2 (da) |
| SI (2) | SI2376121T1 (da) |
| SM (1) | SMT201600156B (da) |
| WO (1) | WO2010071924A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102271705A (zh) * | 2008-12-22 | 2011-12-07 | 墨尔本大学 | 骨关节炎治疗 |
| CA2747206C (en) | 2008-12-22 | 2018-04-24 | The University Of Melbourne | Pain treatment |
| MA37946B1 (fr) | 2012-09-20 | 2018-09-28 | Morphosys Ag | Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde |
| DE102013222200A1 (de) * | 2013-10-31 | 2015-08-27 | Osram Opto Semiconductors Gmbh | Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements |
| JP2020530857A (ja) * | 2017-08-14 | 2020-10-29 | ジナーバ・ファーマシューティカルズ・インコーポレイテッド | 経皮カンナビジオールゲルを用いた変形性関節症の治療方法 |
| WO2020104833A1 (en) * | 2018-11-19 | 2020-05-28 | 4P-Pharma | Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production |
| CN110075304B (zh) * | 2019-05-29 | 2020-02-11 | 四川大学华西医院 | 一种治疗骨关节炎的药物组合物及其用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0482086A1 (en) | 1989-07-14 | 1992-04-29 | Schering Corporation | Antagonists of gm-csf derived from the carboxyl terminus |
| EP0486572B1 (en) | 1989-08-11 | 1998-01-07 | Amrad Corporation Limited | Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| AU5611394A (en) | 1992-11-19 | 1994-06-08 | Dana-Farber Cancer Institute | Antibodies for gm-csf receptor and uses thereof |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| AUPP525198A0 (en) | 1998-08-13 | 1998-09-03 | Medvet Science Pty. Ltd. | Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) * | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| EP1442132A2 (en) * | 2001-10-26 | 2004-08-04 | Novartis AG | Methods for the treatment of osteoarthritis and compositions thereof |
| JP2006500905A (ja) | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化ｇｍ−ｃｓｆ抗体 |
| US20040241755A1 (en) * | 2003-06-02 | 2004-12-02 | Pfizer Inc. | Human cell assay to determine effect of sample compounds on Col2 enhancer expression |
| ATE464908T1 (de) † | 2004-02-11 | 2010-05-15 | Warner Lambert Co | Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern |
| ES2465141T3 (es) * | 2004-03-31 | 2014-06-05 | Kazuwa Nakao | Remedio o medicamento preventivo para la artritis |
| ATE435238T1 (de) | 2004-05-05 | 2009-07-15 | Micromet Ag | Herstellung eines einkettigen fv antikörperfragments |
| WO2006023412A2 (en) | 2004-08-18 | 2006-03-02 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Biomarkers for osteoarthritis |
| US20060040258A1 (en) | 2004-08-23 | 2006-02-23 | Huiyan Guo | Water-soluble conjugates and methods of preparation |
| BRPI0608281B8 (pt) | 2005-04-18 | 2021-05-25 | Amgen Res Munich Gmbh | anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende |
| RU2447085C2 (ru) * | 2005-05-18 | 2012-04-10 | МорфоСис АГ | Анти-gm-csf антитела и их применение |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| EA200801166A1 (ru) * | 2005-12-01 | 2008-12-30 | Домантис Лимитед | Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа |
| US7741450B2 (en) * | 2006-02-08 | 2010-06-22 | Morphotek Inc. | Antibodies to GM-CSF |
| MX2008012291A (es) * | 2006-03-27 | 2009-01-12 | Medimmune Ltd | Miembro que enlaza al receptor gm-csf. |
| US7741273B2 (en) * | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| EP2101780B1 (en) * | 2006-11-21 | 2013-10-09 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| WO2008080134A2 (en) * | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors |
| CN101687926A (zh) * | 2007-05-23 | 2010-03-31 | 哮喘和气道Crc有限公司 | 中和抗体 |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| US20090163440A1 (en) * | 2007-09-26 | 2009-06-25 | Waddell David D | Ion-Channel Regulator Compositions and Methods of Using Same |
| WO2009062238A1 (en) | 2007-11-12 | 2009-05-22 | Crc For Asthma And Airways Ltd | Epitope for neutralizing antibodies |
| CN104072613A (zh) | 2007-11-13 | 2014-10-01 | Evec股份有限公司 | 与hGM-CSF结合的单克隆抗体及包含它的药物组合物 |
| JP2011517672A (ja) † | 2008-03-24 | 2011-06-16 | アボツト・バイオテクノロジー・リミテツド | 骨損失を治療するための方法及び組成物 |
| WO2009134805A2 (en) * | 2008-04-28 | 2009-11-05 | Kalobios Pharmaceuticals, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
| CN102271705A (zh) | 2008-12-22 | 2011-12-07 | 墨尔本大学 | 骨关节炎治疗 |
| CA2747206C (en) † | 2008-12-22 | 2018-04-24 | The University Of Melbourne | Pain treatment |
| US8609101B2 (en) | 2009-04-23 | 2013-12-17 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies |
-
2009
- 2009-12-21 CN CN2009801516359A patent/CN102271705A/zh active Pending
- 2009-12-21 CN CN201610822096.9A patent/CN106397591A/zh active Pending
- 2009-12-21 RU RU2016102339A patent/RU2712273C2/ru active
- 2009-12-21 SI SI200931446A patent/SI2376121T1/sl unknown
- 2009-12-21 KR KR1020177032850A patent/KR101898982B1/ko active Active
- 2009-12-21 AU AU2009329814A patent/AU2009329814B2/en active Active
- 2009-12-21 KR KR1020117017015A patent/KR101799264B1/ko active Active
- 2009-12-21 ES ES15194091T patent/ES2886063T3/es active Active
- 2009-12-21 CA CA2746827A patent/CA2746827C/en active Active
- 2009-12-21 WO PCT/AU2009/001672 patent/WO2010071924A1/en not_active Ceased
- 2009-12-21 BR BRPI0918356-6A patent/BRPI0918356B1/pt active IP Right Grant
- 2009-12-21 HR HRP20160577TT patent/HRP20160577T4/hr unknown
- 2009-12-21 EP EP15194091.3A patent/EP3056217B1/en active Active
- 2009-12-21 PL PL09833924T patent/PL2376121T5/pl unknown
- 2009-12-21 JP JP2011541030A patent/JP5727379B2/ja active Active
- 2009-12-21 ES ES09833924T patent/ES2572368T5/es active Active
- 2009-12-21 HU HUE09833924A patent/HUE028615T2/en unknown
- 2009-12-21 RU RU2011127334/15A patent/RU2011127334A/ru unknown
- 2009-12-21 SI SI200931446T patent/SI2376121T2/sl unknown
- 2009-12-21 EP EP09833924.5A patent/EP2376121B2/en active Active
- 2009-12-21 US US13/140,467 patent/US9243061B2/en active Active
- 2009-12-21 DK DK09833924.5T patent/DK2376121T4/da active
-
2015
- 2015-02-20 JP JP2015031198A patent/JP2015143233A/ja active Pending
- 2015-12-18 US US14/975,024 patent/US20160185868A1/en not_active Abandoned
-
2016
- 2016-05-18 CY CY20161100433T patent/CY1117698T1/el unknown
- 2016-06-01 SM SM201600156T patent/SMT201600156B/it unknown
- 2016-12-06 HK HK16113893.3A patent/HK1226938A1/en unknown
-
2017
- 2017-06-12 JP JP2017114806A patent/JP6458086B2/ja active Active
- 2017-11-13 US US15/811,279 patent/US20180066062A1/en not_active Abandoned
-
2020
- 2020-03-31 US US16/836,464 patent/US20200247895A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200247895A1 (en) | Osteoarthritis treatment | |
| EP2734547B1 (en) | Use of c-fms antagonists | |
| EP2387418B1 (en) | Pain treatment | |
| AU2015224416B2 (en) | Osteoarthritis treatment | |
| HK1162336A (zh) | 骨关节炎治疗 |